Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy

Mikyšková,Romana; Štěpánek,Ivan; Indrová,Marie; Bieblová,Jana; Šímová,Jana; Truxová,Iva; Moserová,Irena; Fučíková,Jitka; Bartůňková,Jiřina; Špíšek,Radek; Reiniš,Milan

doi:10.3892/ijo.2015.3314

Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy

Authors:
- Romana Mikyšková
- Ivan Štěpánek
- Marie Indrová
- Jana Bieblová
- Jana Šímová
- Iva Truxová
- Irena Moserová
- Jitka Fučíková
- Jiřina Bartůňková
- Radek Špíšek
- Milan Reiniš
View Affiliations

Affiliations: Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic, SOTIO a.s., Prague, Czech Republic, Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
Published online on: December 29, 2015 https://doi.org/10.3892/ijo.2015.3314
Pages: 953-964
Copyright: © Mikyšková et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High hydrostatic pressure (HHP) has been shown to induce immunogenic cell death of cancer cells, facilitating their uptake by dendritic cells (DC) and subsequent presentation of tumor antigens. In the present study, we demonstrated immunogenicity of the HHP-treated tumor cells in mice. HHP was able to induce immunogenic cell death of both TC-1 and TRAMP-C2 tumor cells, representing murine models for human papilloma virus-associated tumors and prostate cancer, respectively. HHP-treated cells induced stronger immune responses in mice immunized with these tumor cells, documented by higher spleen cell cytotoxicity and increased IFNγ production as compared to irradiated tumor cells, accompanied by suppression of tumor growth in vivo in the case of TC-1 tumors, but not TRAMP-C2 tumors. Furthermore, HHP-treated cells were used for DC-based vaccine antigen pulsing. DC co-cultured with HHP-treated tumor cells and matured by a TLR 9 agonist exhibited higher cell surface expression of maturation markers and production of IL-12 and other cytokines, as compared to the DC pulsed with irradiated tumor cells. Immunization with DC cell-based vaccines pulsed with HHP-treated tumor cells induced high immune responses, detected by increased spleen cell cytotoxicity and elevated IFNγ production. The DC-based vaccine pulsed with HHP-treated tumor cells combined with docetaxel chemotherapy significantly inhibited growth of both TC-1 and TRAMP-C2 tumors. Our results indicate that DC-based vaccines pulsed with HHP-inactivated tumor cells can be a suitable tool for chemoimmunotherapy, particularly with regard to the findings that poorly immunogenic TRAMP-C2 tumors were susceptible to this treatment modality.

View Figures

View References

1	Ramakrishnan R, Antonia S and Gabrilovich DI: Combined modality immunotherapy and chemotherapy: A new perspective. Cancer Immunol Immunother. 57:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
2	Nowak AK, Lake RA and Robinson BW: Combined chemoimmunotherapy of solid tumours: Improving vaccines? Adv Drug Deliv Rev. 58:975–990. 2006. View Article : Google Scholar : PubMed/NCBI
3	Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature. 392:245–252. 1998. View Article : Google Scholar : PubMed/NCBI
4	Palucka K and Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277. 2012. View Article : Google Scholar : PubMed/NCBI
5	Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L and Kroemer G: Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 1:1111–1134. 2012. View Article : Google Scholar : PubMed/NCBI
6	Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, et al: Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 6:18192–18205. 2015. View Article : Google Scholar : PubMed/NCBI
7	Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J and Spísek R: Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res. 71:4821–4833. 2011. View Article : Google Scholar : PubMed/NCBI
8	Hato SV, Khong A, de Vries IJ and Lesterhuis WJ: Molecular pathways: The immunogenic effects of platinum-based chemo-therapeutics. Clin Cancer Res. 20:2831–2837. 2014. View Article : Google Scholar : PubMed/NCBI
9	Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S and Dhodapkar MV: Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications. Blood. 109:4839–4845. 2007. View Article : Google Scholar : PubMed/NCBI
10	Galluzzi L, Kepp O and Kroemer G: Immunogenic cell death in radiation therapy. Oncoimmunology. 2:e265362013. View Article : Google Scholar
11	Weiss EM, Frey B, Rödel F, Herrmann M, Schlücker E, Voll RE, Fietkau R and Gaipl US: Ex vivo- and in vivo-induced dead tumor cells as modulators of antitumor responses. Ann NY Acad Sci. 1209:109–117. 2010. View Article : Google Scholar : PubMed/NCBI
12	Frey B, Rubner Y, Kulzer L, Werthmöller N, Weiss EM, Fietkau R and Gaipl US: Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother. 63:29–36. 2014. View Article : Google Scholar
13	Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, Fialova A, Sojka L, Cartron PF, Houska M, et al: High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. 135:1165–1177. 2014. View Article : Google Scholar : PubMed/NCBI
14	Emens LA: Chemoimmunotherapy. Cancer J. 16:295–303. 2010. View Article : Google Scholar : PubMed/NCBI
15	Ménard C, Martin F, Apetoh L, Bouyer F and Ghiringhelli F: Cancer chemotherapy: Not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother. 57:1579–1587. 2008. View Article : Google Scholar : PubMed/NCBI
16	van Dodewaard-de Jong JM, Verheul HM, Bloemendal HJ, de Klerk JM, Carducci MA and van den Eertwegh AJ: New treatment options for patients with metastatic prostate cancer: What is the optimal sequence? Clin Genitourin Cancer. 13:271–279. 2015. View Article : Google Scholar : PubMed/NCBI
17	Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI and Jaffee EM: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61:3689–3697. 2001.PubMed/NCBI
18	Malvicini M, Rizzo M, Alaniz L, Piñero F, García M, Atorrasagasti C, Aquino JB, Rozados V, Scharovsky OG, Matar P, et al: A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin Cancer Res. 15:7256–7265. 2009. View Article : Google Scholar : PubMed/NCBI
19	Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
20	Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
21	Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
22	Reinis M, Indrová M, Mendoza L, Mikysková R, Bieblová J, Bubeník J and Símová J: HPV16-associated tumours: Therapy of surgical minimal residual disease with dendritic cell-based vaccines. Int J Oncol. 25:1165–1170. 2004.PubMed/NCBI
23	Reinis M, Stepanek I, Simova J, Bieblova J, Pribylova H, Indrova M and Bubenik J: Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int J Oncol. 36:545–551. 2010. View Article : Google Scholar : PubMed/NCBI
24	Indrová M, Reinis M, Bubeník J, Jandlová T, Bieblová J, Vonka V and Velek J: Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biol (Praha). 50:184–193. 2004.
25	Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21–26. 1996.PubMed/NCBI
26	Foster BA, Gingrich JR, Kwon ED, Madias C and Greenberg NM: Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57:3325–3330. 1997.PubMed/NCBI
27	Lutz MB, Kukutsch N, Ogilvie AL, Rössner S, Koch F, Romani N and Schuler G: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 223:77–92. 1999. View Article : Google Scholar : PubMed/NCBI
28	Stepanek I, Indrova M, Bieblova J, Fucikova J, Spisek R, Bubenik J and Reinis M: Effects of 5-azacytidine and trichostatin A on dendritic cell maturation. J Biol Regul Homeost Agents. 25:517–529. 2011.
29	Yi AK and Krieg AM: CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel. J Immunol. 160:1240–1245. 1998.PubMed/NCBI
30	Reinis M, Símová J, Indrová M, Bieblová J, Pribylová H, Moravcová S, Jandlová T and Bubeník J: Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours. Int J Oncol. 30:1011–1017. 2007.PubMed/NCBI
31	Indrová M, Símová J, Bieblová J, Bubeník J and Reinis M: NK1.1⁺ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours. Oncol Rep. 25:281–288. 2011.
32	Bubenik J, Zeuthen J, Indrova M, Bubenikova D and Simova J: Kinetics and function of peritoneal-exudate cells during local IL-2 gene-therapy of cancer. Int J Oncol. 4:13–16. 1994.PubMed/NCBI
33	Indrová M, Mikysková R, Jandlová T, Vonka V, Bubeník J and Bieblová J: Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: Cytolytic activity of spleen cells from tumour regressors. Folia Biol (Praha). 49:217–222. 2003.
34	Frey B, Janko C, Ebel N, Meister S, Schlücker E, Meyer-Pittroff R, Fietkau R, Herrmann M and Gaipl US: Cells under pressure - treatment of eukaryotic cells with high hydrostatic pressure, from physiologic aspects to pressure induced cell death. Curr Med Chem. 15:2329–2336. 2008. View Article : Google Scholar : PubMed/NCBI
35	Adkins I, Fucikova J, Garg AD, Agostinis P and Špíšek R: Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology. 3:e9684342014. View Article : Google Scholar
36	Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V, Zanovello P, et al: IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine. 28:3548–3557. 2010. View Article : Google Scholar : PubMed/NCBI
37	Okamoto M and Sato M: Toll-like receptor signaling in anti-cancer immunity. J Med Invest. 50:9–24. 2003.PubMed/NCBI
38	Reinis M, Símová J, Indrová M, Bieblová J and Bubeník J: CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours. Int J Oncol. 30:1247–1251. 2007.PubMed/NCBI
39	Spranger S, Javorovic M, Bürdek M, Wilde S, Mosetter B, Tippmer S, Bigalke I, Geiger C, Schendel DJ and Frankenberger B: Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol. 185:738–747. 2010. View Article : Google Scholar : PubMed/NCBI